Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 6, 2020; 8(21): 5494-5495
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5494
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5494
Erratum: Author’s Affiliation Correction. Type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor positive gastric cancer (World J Clin Cases 2019; Aug 6; 7 (15): 1964-1977)
Akio Kaito, Masanori Tokunaga, Reo Sato, Takahiro Kinoshita, Gastric Surgery Division, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Akio Kaito, Takeshi Kuwata, Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Akio Kaito, Kohei Shitara, Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Akio Kaito, Tetsuo Akimoto, Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo 163-8001, Japan
Takeshi Kuwata, Kohei Shitara, Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Tetsuo Akimoto, Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
Author contributions: Kaito A and Kuwata T contributed equally to this correction; i.e., study concepts, study design; all authors contributed equally to manuscript editing and manuscript review.
Conflict-of-interest statement: Not declared.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Takeshi Kuwata, MD, PhD, Doctor, Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1, Kashiwano-ha, Kashiwa 277-8577, Japan. tkuwata@east.ncc.go.jp
Received: July 25, 2020
Peer-review started: July 25, 2020
First decision: September 24, 2020
Revised: September 30, 2020
Accepted: October 20, 2020
Article in press: October 20, 2020
Published online: November 6, 2020
Processing time: 104 Days and 1.7 Hours
Peer-review started: July 25, 2020
First decision: September 24, 2020
Revised: September 30, 2020
Accepted: October 20, 2020
Article in press: October 20, 2020
Published online: November 6, 2020
Processing time: 104 Days and 1.7 Hours
Core Tip
Core Tip: This manuscript is an author's affiliation correction for type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor positive gastric cancer (World J Clin Cases 2019; Aug 6; 7 (15): 1964-1977).